Jennifer Postelnek
About Jennifer Postelnek
Jennifer Postelnek is a Research Scientist II specializing in BioAnalytical Sciences at Bristol-Myers Squibb in Princeton, New Jersey.
Current Position at Bristol Myers Squibb
Jennifer Postelnek currently holds the position of Principal Scientist at Bristol Myers Squibb, located in Princeton, New Jersey. She specializes in BioAnalytical Sciences, focusing on Biologics and Biomarker Development. Her role involves developing and validating novel immuno-assays for biomarker evaluation to support discovery programs and clinical trials.
Previous Roles at Bristol Myers Squibb
Jennifer Postelnek has a long history with Bristol Myers Squibb. In addition to her current role, she has previously worked as a Senior Research Scientist I in 2018 for a brief period. Earlier, she served as an Associate Research Scientist II from 1999 to 2005, where she made significant contributions to various research initiatives.
Previous Experience at Pharmaceutical Companies
Jennifer Postelnek has accumulated extensive experience in the pharmaceutical industry. She worked at Roche Pharmaceuticals as an Associate Principal Scientist from 2009 to 2012. Prior to that, she was an Associate Scientist at Pharmacopeia from 2005 to 2009 and started her career as a Research Associate II at HTI Bioservices from 1997 to 1998.
Education and Expertise
Jennifer Postelnek earned her Bachelor's degree in Biological Sciences and English from Rutgers, The State University of New Jersey-New Brunswick. She has expertise in pharmacodynamic and disease model development, particularly in inflammation models of cytokine production, cell recruitment, transplantation, and arthritis. Additionally, she possesses experience in pharmacokinetics, cardiovascular, pain, and toxicology.
Technical Skills and Methods
Jennifer Postelnek is proficient in utilizing technologies like ForteBio and multiple automation systems. She is experienced with several assay platforms, including electrochemiluminescence and multiplexing. As the technical owner of outsourced biomarker analysis, she collaborates closely with Clinical Biomarker leads and CROs. Furthermore, her ex vivo experience encompasses mammalian cell culture, co-culture, and whole blood assays.